Omalizumab outcomes for up to 6 years in pediatric patients with severe persistent allergic asthma.
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Garriga-Baraut T
- Plaza Martín AM
- Torres Borrego J
- Del Mar Folqué Giménez M
- Lozano Blasco J
- Bosque García M
- Moreno-Galarraga L
- Tortajada-Girbés M
- Rivas Juesas C
- Penín Antón M
- Caballero-Rabasco MA
- Gaboli M
- López Neyra A
- Navarro Morón J
- Freixa A
- Valdesoiro Navarrete L
- Ballester Asensio E
- Sanz Santiago V
- Romero García R
- Gimeno Díaz de Atauri Á
- Valenzuela Soria A
- Sánchez Mateos M
- Batlles Garrido J
- Andrés Martín A
- Campos Alonso E
- Aragón Fernández C
- Vázquez Rodríguez E
- Martínez Pardo L
- Del Río Camacho G
Grupos
Abstract
Various studies have assessed omalizumab outcomes in the clinical practice setting but follow-up and/or number of patients included were limited. We aim to describe the long-term outcomes of pediatric patients with severe persistent allergic asthma receiving omalizumab in the largest real-life cohort reported to date.
Datos de la publicación
- ISSN/ISSNe:
- 0905-6157, 1399-3038
- Tipo:
- Article
- Páginas:
- 980-991
- DOI:
- 10.1111/pai.13484
- PubMed:
- 33619748
- Factor de Impacto:
- 1,264 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
PEDIATRIC ALLERGY AND IMMUNOLOGY WILEY-BLACKWELL PUBLISHING, INC
Citas Recibidas en Web of Science: 32
Documentos
- No hay documentos
Filiaciones
Keywords
- Children, adolescents, anti-asthmatic agents, humanized monoclonal antibodies, observational study, omalizumab, real-life, severe asthma
Cita
NIETO A,Garriga T,Plaza AM,NIETO M,Torres J,Del Mar M,Lozano J,Bosque M,Moreno L,Tortajada M,Rivas C,Penín M,Caballero MA,Gaboli M,López A,Navarro J,Freixa A,Valdesoiro L,Ballester E,Sanz V,Romero R,Gimeno Díaz de Atauri Á,Valenzuela A,Sánchez M,Batlles J,Andrés A,Campos E,Aragón C,Vázquez E,Martínez L,Del Río G,MAZÓN Á. Omalizumab outcomes for up to 6 years in pediatric patients with severe persistent allergic asthma. Pediatr. Allergy Immunol. 2021. 32. (5):p. 980-991. IF:5,464. (1).
Portal de investigación